Clinical Characteristics, Risk Factors for Severity and Pharmacotherapy in Hospitalized COVID-19 Patients in the United Arab Emirates.
COVID-19
United Arab Emirates
biomarkers
clinical characteristics
pharmacotherapy
risk factors
severity
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
26 Apr 2022
26 Apr 2022
Historique:
received:
29
03
2022
revised:
17
04
2022
accepted:
20
04
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
15
5
2022
Statut:
epublish
Résumé
Data on the clinical characteristics, severity and management of COVID-19 from the Middle East region, especially the United Arab Emirates (UAE), is very limited. We studied the clinical characteristics, laboratory biomarkers, risk factors for severity and pharmacotherapy of hospitalized COVID-19 patients in this single-center, analytical cross-sectional study conducted in a secondary care hospital of the UAE. A total of 585 patients were included in the study (median age, 49 years (IQR, 39−59); 66% male). Age > 45 years (OR = 2.07, 95% CI: 1.04−4.14, p = 0.040), male gender (OR = 3.15, 95% CI: 1.52−6.51, p = 0.002), presentation symptoms such as fever (OR = 3.68, 95% CI:1.34−10.11, p = 0.011) and shortness of breath/dyspnea (OR = 5.36, 95% CI: 2.69−10.67, p < 0.001), Hb < 13 g/dL (OR = 3.17, 95% CI: 1.51−6.65, p = 0.002), neutrophils > 7 × 103/mcL (OR = 4.89, 95% CI: 1.66−14.37, p=0.004), lymphocytes < 1 × 103/mcL (OR = 7.78, 95% CI: 1.01−60.19, p = 0.049), sodium < 135 mmol/L (OR = 5.42, 95% CI: 1.05−27.95, p = 0.044), potassium < 3.6 mmol/L (OR = 3.36, 95% CI: 1.03−11.01, p = 0.045), urea > 6.5 mmol/L (OR = 3.37, 95% CI: 1.69−6.73, p = 0.001) and LDH > 227 IU/L (OR = 6.26, 95% CI: 1.61−24.32, p = 0.008) were independent predictors of the severity of COVID-19. Antivirals (524, 89.6%) and corticosteroids (358, 61.2%) were prescribed for the management of COVID-19. In conclusion, older age, male gender, presentation symptoms such as fever and dyspnea, low hemoglobin, neutrophilia, lymphopenia, hyponatremia, hypokalemia, elevated levels of urea and lactate dehydrogenase were found to be independent risk factors for severe COVID-19. The pharmacotherapy of COVID-19 patients in our study was diverse, and the medications were prescribed based on the clinical condition of the patients.
Identifiants
pubmed: 35566563
pii: jcm11092439
doi: 10.3390/jcm11092439
pmc: PMC9100822
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Hepatology. 2020 Aug;72(2):389-398
pubmed: 32359177
Am J Emerg Med. 2021 Apr;42:60-69
pubmed: 33453617
Nat Commun. 2020 Dec 9;11(1):6317
pubmed: 33298944
Acta Biomed. 2020 Sep 07;91(3):e2020008
pubmed: 32921706
BMC Infect Dis. 2020 Aug 31;20(1):640
pubmed: 32867706
N Engl J Med. 2020 Nov 19;383(21):2041-2052
pubmed: 32706953
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Microbes Infect. 2020 Oct;22(9):481-488
pubmed: 32561409
Ann Transl Med. 2021 Feb;9(4):306
pubmed: 33708933
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
New Microbes New Infect. 2020 Sep;37:100753
pubmed: 32904987
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Am J Emerg Med. 2020 Sep;38(9):1722-1726
pubmed: 32738466
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Infect. 2020 Aug;81(2):e16-e25
pubmed: 32335169
Innovation (Camb). 2020 May 21;1(1):100007
pubmed: 33554186
Liver Int. 2020 Sep;40(9):2095-2103
pubmed: 32239796
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Engineering (Beijing). 2020 Oct;6(10):1192-1198
pubmed: 32346491
EClinicalMedicine. 2020 Aug;25:100471
pubmed: 32840491
Drugs. 2020 Dec;80(18):1961-1972
pubmed: 33151482
Clin Epidemiol Glob Health. 2021 Jul-Sep;11:100727
pubmed: 33778183
Int J Infect Dis. 2021 Apr;105:516-521
pubmed: 33713817
Front Pharmacol. 2021 Sep 02;12:683296
pubmed: 34539392
Lab Med. 2021 Jan 4;52(1):10-15
pubmed: 32929506
QJM. 2021 Dec 20;114(10):706-714
pubmed: 33533902
Am J Hematol. 2020 Jul;95(7):834-847
pubmed: 32282949
Diabetes Care. 2021 Feb;44(2):526-532
pubmed: 33268335
Int Immunopharmacol. 2021 Jan;90:107233
pubmed: 33290963
Hepatol Res. 2020 Aug;50(8):924-935
pubmed: 32386449
Epidemiol Infect. 2020 Jul 07;148:e146
pubmed: 32631458
Wien Klin Wochenschr. 2021 Apr;133(7-8):377-382
pubmed: 33242148
Sci Rep. 2021 Apr 13;11(1):8059
pubmed: 33850184
N Engl J Med. 2020 Nov 19;383(21):2030-2040
pubmed: 33031652
Int J Environ Res Public Health. 2020 Nov 28;17(23):
pubmed: 33260724
Front Med (Lausanne). 2020 Dec 09;7:585003
pubmed: 33363185
Signal Transduct Target Ther. 2020 Mar 27;5(1):33
pubmed: 32296069
Transfus Apher Sci. 2020 Dec;59(6):102926
pubmed: 32893135
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
N Engl J Med. 2020 Jun 18;382(25):2411-2418
pubmed: 32379955
PLoS One. 2021 Apr 6;16(4):e0249788
pubmed: 33822812
Int J Infect Dis. 2020 Jul;96:467-474
pubmed: 32425643
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Chin Med J (Engl). 2020 Jun 5;133(11):1261-1267
pubmed: 32209890
BMC Infect Dis. 2022 Feb 8;22(1):136
pubmed: 35135491
BMJ Open. 2021 Jan 11;11(1):e044640
pubmed: 33431495
Lancet Reg Health Eur. 2021 May;4:100105
pubmed: 33969336
Br J Clin Pharmacol. 2021 Dec;87(12):4737-4746
pubmed: 33982806
Int J Infect Dis. 2020 Nov;100:449-454
pubmed: 32950739
Int J Lab Hematol. 2020 Oct;42(5):e207-e210
pubmed: 32803875